公开(公告)号：EP1257282A4

公开(公告)日：2003-05-02

申请号：EP00980985

申请日：2000-12-06

申请人： GEN HOSPITAL CORP

发明人： ABRAHAM ELIZABETH J ,  FAUSTMAN DENISE ,  HABENER JOEL L ,  VALLEJO MARIO ,  ZULEWSKI HENDRIK ,  THOMAS MELISSA K

IPC分类号： C12N15/09 ,  A01K67/027 ,  A61K20060101 ,  A61K31/436 ,  A61K31/7088 ,  A61K35/12 ,  A61K35/39 ,  A61K38/00 ,  A61K38/22 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P3/10 ,  A61P37/06 ,  A61P43/00 ,  C12N20060101 ,  C12N5/02 ,  C12N5/071 ,  C12N5/074 ,  C12Q1/00 ,  G01N33/53 ,  A61K35/00 ,  C12N15/85

CPC分类号： C12N5/0676 ,  A01K67/0271 ,  A61K35/12 ,  A61K2035/122 ,  C12N5/0677 ,  C12N5/0678 ,  C12N2500/34 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/335 ,  C12N2510/02

摘要： Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.

公开(公告)号：EP1438418A4

公开(公告)日：2005-12-21

申请号：EP02768905

申请日：2002-09-26

申请人： GEN HOSPITAL CORP

发明人： HABENER JOEL F ,  ZULEWSKI HENRYK ,  THOMAS MELISSA K ,  ABRAHAM ELIZABETH J ,  VALLEJO MARIO ,  LEECH COLIN A ,  NOLAN ANNA LOUISE ,  LECHNER ANDREAS

IPC分类号： C12N15/09 ,  A01K67/027 ,  A61K20060101 ,  A61K31/436 ,  A61K31/7088 ,  A61K35/12 ,  A61K35/39 ,  A61K38/00 ,  A61K38/22 ,  A61K45/00 ,  A61K48/00 ,  A61P3/10 ,  C12N20060101 ,  C12N5/02 ,  C12N5/074 ,  C12Q1/00 ,  G01N33/53

CPC分类号： A01K67/0271 ,  A61K35/12 ,  A61K2035/122 ,  C12N5/0678 ,  C12N2500/34 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/335 ,  C12N2510/02

摘要： Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.